Feasibility of Acquiring Hyperpolarized Imaging in Patients With Primary CNS Lymphoma
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
This phase I trial evaluates the feasibility of using hyperpolarized carbon C 13 pyruvate magnetic resonance imaging (MRI) in diagnosing patients with primary central nervous system lymphoma. This trial aims to see whether MRI using hyperpolarized carbon-13 pyruvate is safe and useful for detecting central nervous system lymphoma and evaluating response to treatment.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Wiek powyżej 18 lat i spodziewana długość życia ponad 12 tygodni
- •Potwierdzony wcześniej chłoniak mózgu (NHL typu DLBCL)
- •Widoczny guz w MRI o średnicy co najmniej 1 cm
- •Wystarczająca funkcja nerek (kreatynina powyżej 50 ml/min badana w ciągu 21 dni)
- •Kwalifikacja do leczenia wysokimi dawkami metotreksatu
- •Podpisana zgoda na udział w badaniu
✗ Disqualifies
- •Poważne choroby serca (niewydolność serca stopnia II lub wyższego)
- •Inne poważne schorzenia, które mogłyby uniemożliwić uczestnictwo w badaniu lub zagrażać bezpieczeństwu
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- July 14, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (1)
University of California, San Francisco
San Francisco, United States
Trial contact
Wendy Ma
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/15/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.